The conclusion that RB1 loss increases dependence on BCL-XL is also strongly supported by large scale drug screening data from the Sanger Institute Genomics of Drug Sensitivity in Cancer and Broad DepMap. The gene discussed is BCL2L1; the disease is cancer.